Arrowhead and Takeda will jointly develop ARO-AAT to treat alpha-1 antitrypsin-associated liver disease. If successful, the companies will license the drug in the U.S. and share the 50/50 profit. Outside the U.S., Takeda will become a major supplier of ARO-AAT. Closing the deal is dependent on the completion of an antitrust review.